2004
DOI: 10.1038/modpathol.3800043
|View full text |Cite
|
Sign up to set email alerts
|

Microphthalmia transcription factor and NKI/C3 expression in cellular neurothekeoma

Abstract: While the usual or myxoid-type neurothekeoma has been reasonably well established as being a tumor of neural origin, the cellular neurothekeoma remains in disputed histogenesis. We studied a series of 11 cellular neurothekeomas using paraffin immunoperoxidase staining with microphthalmia transcription factor (Mitf), NKI/C3, and S-100. The majority of the tumors in our series stained with NKI/C3 (9/11) and Mitf (9/11). All failed to stain with S-100. Furthermore, we divided our series of cellular neurothekeomas… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

1
41
0

Year Published

2008
2008
2022
2022

Publication Types

Select...
5
4

Relationship

0
9

Authors

Journals

citations
Cited by 64 publications
(42 citation statements)
references
References 25 publications
(19 reference statements)
1
41
0
Order By: Relevance
“…Our own experience with recently proposed markers of utility for the same such as CD10 and CD99 is that they are inconsistently expressed and also expressed in a number of other lineageunrelated neoplasms. [23][24][25][26] Speculative as it may seem, given that we did not study ApoD expression in other atypical spindled cell neoplasms, the consistently strong positive Apo D staining (3 þ , 80%) in cases of atypical fibroxanthoma suggests that this marker holds some promise in terms of diagnostic utility.…”
Section: Discussionmentioning
confidence: 91%
“…Our own experience with recently proposed markers of utility for the same such as CD10 and CD99 is that they are inconsistently expressed and also expressed in a number of other lineageunrelated neoplasms. [23][24][25][26] Speculative as it may seem, given that we did not study ApoD expression in other atypical spindled cell neoplasms, the consistently strong positive Apo D staining (3 þ , 80%) in cases of atypical fibroxanthoma suggests that this marker holds some promise in terms of diagnostic utility.…”
Section: Discussionmentioning
confidence: 91%
“…2,3,5,23,24 In our series, all of the cases tested were at least focally positive for NKI-C3 and 29/30 (97%) were positive for CD10. This parallels what has been previously reported in the literature.…”
Section: Discussionmentioning
confidence: 92%
“…Immunoreactivity for MiTF has been seen in 81-100% of cellular neurothekeoma. 23,29 In this series, two of three cases tested were positive for MiTF. Immunostains for CD68 are insufficiently sensitive, as just under half of the cases tested were positive (6/13).…”
Section: Discussionmentioning
confidence: 99%
“…42,43 More recently developed markers such as MiTF and/or SOX10 may also be of value in selected cases, although these markers lack perfect specificity for melanoma. [44][45][46][47][48] In our experience, two other scenarios where aberrant marker Aberrant marker expression in melanoma expression in melanoma causes difficulty is when the referring pathologist hasn't considered the possibility of melanoma or is simply unaware that this may happen. Failing to include melanoma in the differential diagnosis seems most often to happen for lesions occurring in non-cutaneous locations (especially the sinonasal region and viscera), in the metastatic setting when a prior history of melanoma has not been provided, and in exclusively spindled or round cell (small cell) melanomas.…”
Section: Modern Pathology (2015) 28 1033-1042mentioning
confidence: 99%